Half-life extension technologies for haemostatic agents

Thrombosis and Haemostasis

Volumn 113, Issue 1, 2015, Pages 165-176

  Mannucci, Pier Mannuccio ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Coagulation factors; Haemophilia; Prolonged half life

Indexed keywords

ALBUMIN; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CARBOXYLTERMINAL PEPTIDE; HEMOSTATIC AGENT; HETASTARCH; HYBRID PROTEIN; IMMUNOGLOBULIN G; MACROGOL; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; BLOOD CLOTTING FACTOR; COAGULATING AGENT;

ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING; CLINICAL EVALUATION; CLINICAL TRIAL; DRUG EFFICACY; HALF LIFE TIME; HEMOPHILIA; HEMOSTASIS; HUMAN; IMMUNOGENICITY; KIDNEY CLEARANCE; META ANALYSIS; PRIORITY JOURNAL; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ANIMAL; BLOOD; DRUG ADMINISTRATION; DRUG EFFECTS; HEMOPHILIA A; HEMOPHILIA B; INTRAVENOUS DRUG ADMINISTRATION; PROTEIN DEGRADATION; PROTEIN STABILITY;

ANIMALS; BLOOD COAGULATION FACTORS; COAGULANTS; DRUG ADMINISTRATION SCHEDULE; HALF-LIFE; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMANS; INFUSIONS, INTRAVENOUS; PROTEIN STABILITY; PROTEOLYSIS; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 84922344119     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-04-0332     Document Type: Article

References (119)

1. Fischer K, et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 2002; 8: 745-752.
2. Gringeri A, et al. Health status and health-related quality of life of children with haemophilia from six West European countries. Haemophilia 2004; 10 (Suppl 1): 26-33.
3. Gringeri A, et al. A randomized clinical trial of prophylaxis in children with haemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700-710.
4. Ljung R. Prophylactic therapy in haemophilia. Blood Rev 2009; 23: 267-274.
5. Mannucci PM, et al. How do we choose factor VIII to treat haemophilia. Blood 2012; 119: 4108-4114.
6. Guh S, et al. Healthcare expenditures for males with haemophilia and employersponsored insurance in the United States, 2008. Haemophilia 2012; 18: 268-275.
7. Guh S, et al. Health care expenditures for Medicaid-covered males with haemophilia in the United States, 2008. Haemophilia 2012; 18: 276-283.
8. Morfini M. Pharmacokinetics of factor VIII and factor IX. Haemophilia 2003; 9 (Suppl 1): 94-99.
9. Pipe SW. The hope and reality of long-acting haemophilia products. Am J Hematol 2012; 87 (Suppl 1): S33-S39.
10. Moher D, et al. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. Ann Intern Med 2009; 151: 264-269.
11. Dumont JA, et al. Prolonged activity of a recombinant factor VIII-Fc fusion protein in haemophilia A mice and dogs. Blood 2012; 119: 3024-3030.
12. van der Flier A, et al. VWF affects the clearance and biodistribution of recombinant factor VIII Fc fusion (rFVIIIFc). J Thromb Haemost 2013; 11 (Suppl 2): 476 (Abstract PA 4.13-6).
13. Peters RT, et al. Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein. J Thromb Haemost 2013; 11: 132-141.
14. Powell JS, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in haemophilia A patients. Blood 2012; 119: 3031-3037.
15. Mahlangu J, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe haemophilia A. Blood 2014; 123: 317-325.
16. Mahlangu J, et al. Long-lasting recombinant factor VIII Fc fusion (rFVIIIFc) for perioperative management of subjects with haemophilia A in the phase 3 A-LONG study. J Thromb Haemost 2013; 11 (Suppl 2): 459 (Abstract PA 2.07-4).
17. Buyue Y, et al. Evaluation of the thrombin generation potential of a recombinant factor VIII Fc fusion protein (rFVIIIFc) in a phase III multi-national clinical trial. J Thromb Haemost 2013; 11 (Suppl 2): 228 (Abstract OC 64.3).
18. Sommer J, et al. Evaluation of whole blood clotting activity of recombinant factor VIII Fc fusion protein by ROTEM analysis in a multi-center Phase 3 clinical trial. J Thromb Haemost 2013; 11 (Suppl 2): 39 (Abstract AS 26.1).
19. Peters RT, et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 2010; 115: 2057-2064.
20. Shapiro AD, et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in haemophilia B patients. Blood 2012; 119: 666-672.
21. Powell JS, et al. Phase 3 study of recombinant factor IX Fc fusion protein in haemophilia B. N Engl J Med 2013; 369: 2313-2323.
22. Pasi J, et al. Treatment of bleeding episodes in subjects with haemophilia B with the long-lasting recombinant factor IX Fc fusion protein (rFIXFc) in the phase 3 B-LONG study. J Thromb Haemost 2013; 11 (Suppl 2): 359 (Abstract PA 2.07-6).
23. Powell J, et al. Long-lasting recombinant factor FIX Fc fusion (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study. J Thromb Haemost 2013; 11 (Suppl 2): 358 (Abstract PA 2.07-4).
24. Li S, et al. Clinical implications of population pharmacokinetics of rFIXFc in routine prophylaxis, control of bleeding and perioperative management for haemophilia B patients. J Thromb Haemost 2013; 11 (Suppl 2): 358 (Abstract PA 2.07-5).
25. Salas J, et al. Enhanced pharmacokinetics of factor VIIA as a monomeric FC fusion. J Thromb Haemost 2011; 9 (Suppl 2): 268 (Abstract O-TU-026).
26. Bain VG, et al. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol 2006; 44: 671-678.
27. Sheffield WP, et al. Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits. Br J Haematol 2004; 126: 565-573.
28. Metzner HJ, et al. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost 2009; 102: 634-644.
29. Nolte MW, et al. Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and haemophilia B dogs. J Thromb Haemost 2012; 10: 1591-1599.
30. Herzog E, Harris S, Hensen C, et al. Biodistribution of recombinant fusion protein linking recombinant factor IX with albumin (rIX-FP) in rats. Thromb Res 2014; 133: 900-907.
31. Santagostino E, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in haemophilia B patients. Blood 2012; 120: 2405-2411.
32. Santagostino E. PROLONG-9FP clinical development program--phase I results of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP). Thromb Res 2013; 131 (Suppl 2): S7-10.
33. Martinowitz U, Lubetsky A. Phase I/II, open-label, multicenter, safety, efficacy and PK study of a recombinant coagulation factor IX albumin fusion protein (rIX-FP) in subjects with haemophilia B. Thromb Res 2013; 131 (Suppl 2): S11-14.
34. Martinowitz U, et al. Efficacy, PK and safety results of a Phase I/II clinical study of recombinant fusion protein linking coagulation factor IX with albumin (rIXFP) in previously treated patients with haemophilia B. J Thromb Haemost 2013; 11 (Suppl 2): 240-241 (Abstract OC 70.2).
35. Horn C, et al. Concept and structure model of factor VIIa albumin fusion proteins. Haemophilia 2010; 16 (Suppl 4): 37 (Abstract 08P19).
36. Schulte S. Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa. Thromb Res 2008; 122 (Suppl 4): S14-S19.
37. Weimer T, et al. Prolonged in-vivo half-life of factor VIIa by fusion to albumin. Thromb Haemost 2008; 99: 659-667.
38. Zollner S, et al. Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP). J Thromb Haemost 2014; 12: 220-228.
39. Herzog E, et al. Quantitative whole body autoradiography (QWBA) study on the biodistribution of a recombinant factor rVIIa linked to human albumin. J Thromb Haemost 2103; 11 (Suppl 2): 587 (Abstract PB 1.58-3).
40. Golor G, et al. Safety and Pharmacokinetics of a Recombinant Fusion Protein Linking Coagulation Factor VIIa with Albumin (rVIIa-FP) in Healthy Volunteers. J Thromb Haemost 2013; 11: 1977-1985.
41. Schulte S. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII. Thromb Res 2013; 131 (Suppl 2): S2-S6.
42. Stennicke HR, et al. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in haemophilic mice models. Blood 2013; 121: 2108-2116.
43. Krogh-Meibom T, et al. The activity of glycoPEGylated recombinant FVIII (N8-GP) can be measured in both two-stage chromogenic and one-stage clotting assays. J Thromb Haemost 2013; 11 (Suppl 2): 1042 (Abstract PO 059).
44. Agerso H, et al. Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs. Haemophilia 2012; 18: 941-947.
45. Johansen PB, et al. Dose response relationship and duration of effect of a PEGylated recombinant FVIII conjugate, N8-GP, in a new tail vein transection bleeding model in anaesthetized FVIII k/o mice. J Thromb Haemost 2013; 11 (Suppl 2): 475 (Abstract PA 4.13-3).
46. Tiede A, et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with haemophilia A. J Thromb Haemost 2013; 11: 670-678.
47. Mei B, et al. Rational design of a fully active, long-acting PEGylated factor VIII for haemophilia A treatment. Blood 2010; 116: 270-279.
48. Coyle T, et al. An open-label phase I study to evaluate the pharmacokinetics and safety profile of Bay 94-9027, a PEGylated B-domain-deleted recombinant factor VIII, in previously treated patients with severe haemophilia A. Haemophilia 2012; 18 (Suppl 3): 22 (Abstract FP-MO-03.2-3).
49. Paz P, et al. PEGylated FVIII Exhibits Reduced Immunogenicity in Haemophilia A Mice and In Vitro in Human Cells. Haemophilia 2012; 18 (Suppl 3): 93 (Abstract PO-WE-125).
50. Turecek PL, et al. BAX 855, a PEGylated rFVIII product with prolonged halflife. Development, functional and structural characterisation. Hamostaseologie 2012; 32 (Suppl 1): S29-S38.
51. Dietrich B, et al. Preclinical safety of a longer acting recombinant factor VIII (BAX 855). J Thromb Haemost 2013; 11 (Suppl 2): 844 (Abstract PB 3.55-4).
52. Stidl R, et al. PEGylated biopharmaceuticals and safety evaluation of polyethylene glycol (PEG) with focus on PEG-rFVIII. J Thromb Haemost 2013; 11 (Suppl 2): 845 (Abstract PB 3.55-6).
53. Horlin F, et al. The use of novel models for preclinical immunogenicity assessment of a longer-acting FVIII candidate. Haemophilia 2012; 18 (Suppl 3): 90 (Abstract PO-WE-107).
54. Turecek PL, et al. Structural and functional characterization of clinical phase 1 and phase 2/3 material of BAX 855, a PEGylated recombinant FVIII. J Thromb Haemost 2013; 11 (Suppl 2): 922-923 (Abstract PB 4.35-2).
55. Negrier C, et al. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with haemophilia B. Blood 2011; 118: 2695-2701.
56. Ostergaard H, et al. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. Blood 2011; 118: 2333-2341.
57. Collins PW, et al. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX. J Thromb Haemost 2012; 10: 2305-2312.
58. Collins PW, et al. Safety, efficacy and pharmacokinetics of nonacog beta pegol (N9-GP) for prophylaxis and treatment of bleeding episodes in patients with haemophilia B. J Thromb Haemost 2013; 11 (Suppl 2): 19 (Abstract AS 12.4).
59. Novo Nordisk. Novo Nordisk press release. 17 May 2013. Available at: http://www.novonordisk.com/include/asp/exe_news_attachment.asp?sAttachmentGUID=BD0FD957-1FD8-4B8E-A8CE-07BCB7E23A33. Accessed March 2014.
60. Novo Nordisk. Novo Nordisk press release. Available at: http://www.novonordisk.com/images/investors/investor_presentations?2011/Q3/PR111027_9M_2011_UK.pdf. Accessed July 2013.
61. Stennicke HR, et al. Generation and biochemical characterization of glyco-PEGylated factor VIIa derivatives. Thromb Haemost 2008; 100: 920-928.
62. Sen P, et al. Effect of glycoPEGylation on factor VIIa binding and internalization. Haemophilia 2010; 16: 339-348.
63. Holmberg H, et al. GlycoPEGylated rFVIIa (N7-GP) has a prolonged hemostatic effect in haemophilic mice compared with rFVIIa. J Thromb Haemost 2011; 9: 1070-1072.
64. Johansen PB, et al. Prolonged effect of GlycoPEGylated rFVIIa (40k-PEGrFVIIa) in rabbits correlates to activity in plasma. Thromb Haemost 2010; 104: 157-164.
65. Karpf DM, Sorensen BB, Hermit MB, et al. Prolonged half-life of glycoPEGylated rFVIIa variants compared to native rFVIIa. Thromb Res 2011; 128: 191-195.
66. Moss J, et al. Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects. J Thromb Haemost 2011; 9: 1368-1374.
67. Ljung R, et al. 40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in haemophilia patients with inhibitors. J Thromb Haemost 2013; 11: 1260-1268.
68. Yatuv R, et al. The use of PEGylated liposomes in the development of drug delivery applications for the treatment of haemophilia. Int J Nanomedicine 2010; 5: 581-591.
69. Barenholz Y. Doxil(R)--the first FDA-approved nano-drug: lessons learned. J Control Release 2012; 160: 117-134.
70. Lacerda JF, Oliveira CM. Diagnosis and treatment of invasive fungal infections focus on liposomal amphotericin B. Clin Drug Investig 2013; 33 (Suppl 1): S5-14.
71. Baru M, et al. Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy. Thromb Haemost 2005; 93: 1061-1068.
72. Dayan I, et al. Enhancement of haemostatic efficacy of plasma-derived FVIII by formulation with PEGylated liposomes. Haemophilia 2009; 15: 1006-1013.
73. Pan J, et al. Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in haemophilia A mice. Blood 2009; 114: 2802-2811.
74. Peng A, et al. PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in haemophilia A mice. AAPS J 2012; 14: 35-42.
75. Ramani K, et al. Passive transfer of polyethylene glycol to liposomal-recombinant human FVIII enhances its efficacy in a murine model for haemophilia A. J Pharm Sci 2008; 97: 3753-3764.
76. Martinowitz U, et al. Infusion rates of recombinant FVIII-FS with PEGylated liposomes in haemophilia A. Haemophilia 2008; 14: 1122-1124.
77. Spira J, et al. Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes. Blood 2006; 108: 3668-3673.
78. Powell JS, et al. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe haemophilia A. J Thromb Haemost 2008; 6: 277-283.
79. Spira J, et al. Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A. Thromb Haemost 2008; 100: 429-434.
80. Powell J, et al. Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study. Thromb Haemost 2012; 108: 913-922.
81. Yatuv R, et al. Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes. Haemophilia 2008; 14: 476-483.
82. Spira J, et al. Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II study. Haemophilia 2010; 16: 910-918.
83. Dasgupta S, et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood. 2007; 109: 610-612.
84. Schmidbauer S, et al. N-Glycosylation of rVIII-SingleChain, a novel recombinant single-chain factor VIII. J Thromb Haemost 2013; 11 (Suppl 2): 713 (Abstract PB 2.55-6).
85. Zollner S, et al. Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII. Thromb Res. 2014; 134: 125-131.
86. Zollner SB, et al. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII. Thromb Res 2013; 132: 280-287.
87. Pabinger I, et al. Pharmacokinetics results of a phase I/III study of a novel recombinant single chain factor VIII (rVIII-SingleChain) compared to octocog alfa in severe haemophilia A patients. J Thromb Haemost 2013; 11 (Suppl 2): 712 (Abstract PB 2.55-4).
88. Hart G, et al. FVIIa-CTP and FIX-CTP are novel long-acting coagulation factors with prolonged hemopstatic activity in haemophilic animal models. Haemophilia 2012; 18 (Suppl 3): 32 (Abstract PO-TU-025).
89. Hart G, et al. A long-acting FVIIa-CTP proposing an improved prophylactic and on demand treatment for haemophilic patients following SC and IV administration-evaluation in animal models. J Thromb Haemost 2013; 11 (Suppl 2): 268 (Abstract OC 83.6).
90. Van der Linden P, et al. Safety of modern starches used during surgery. Anesth Analg 2013; 116: 35-48.
91. Sommer J, et al. Preservation of activity and prolonged efficacy of rFVIII after site-specific modification with high molecular weight hydroxyethyl starch. Haemophilia 2010; 16 (Suppl 4): 39 (Abstract 08P35).
92. Hey T, Hackett F. Prolonged circulatory half life for rFVIIa after conjugation to hydroxyethyl starch. Haemophilia 2010; 16 (Suppl 4): 36 (Abstract 08P16).
93. Liu T, et al. A combinatorial library approach to generate rFVIII variants with multiple XTEN insertions and improved pharmacokinetic properties. J Thromb Haemost 2013; 11 (Suppl 2): 371 (Abstract PA 2.12-5).
94. Tan S, et al. A platelet-targeted factor VIIa. XTEN fusion protein with increased circulating half-life and improved clotting activity. J Thromb Haemost 2013; 11 (Suppl 2): 586 (Abstract PB 1.58-1).
95. Dallabrida S, et al. Recombinant FVIIa-XTEN as a long-lasting form of rFVIIa with an enhanced PK profile. Haemophilia 2012; 18 (Suppl 3): 28 (Abstract FPTU-01.1-2).
96. Flintegaard TV, et al. N-glycosylation increases the circulatory half-life of human growth hormone. Endocrinology 2010; 151: 5326-5336.
97. Bolt G, et al. Hyperglycosylation prolongs the circulation of coagulation factor IX. J Thromb Haemost 2012; 10; 2397-2398.
98. Andersen JT, et al. Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor. Nat Commun 2012; 3: 610.
99. Krishnan S, Miners A. Comparing projected prophylactic consumption and effects of recombinant factor VIII Fc Fusion (rFVIIIFc) and shorter half-life FVIII products in haemophilia. J Thromb Haemost 2013; 11 (Suppl 1): 844-845 (Abstract PB 3.55-5).
100. Houde D, Berkowitz SA. Conformational comparability of factor IX-Fc fusion protein, factor IX, and purified Fc fragment in the absence and presence of calcium. J Pharm Sci 2012; 101: 1688-1700.
101. Collins PW, et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe haemophilia A: in_uences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost 2009; 8: 269-275.
102. Ahnström J, et al. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia 2004; 10: 689-697.
103. Hubbard AR. International biological standards for coagulation factors and inhibitors. Semin Thromb Hemost 2007; 33: 283-289.
104. Hubbard AR, et al. Recommendations on the potency labelling of factor VIII and factor IX concentrates. J Thromb Haemost 2013; 11: 988-989.
105. Flori N, et al. Pegylated interferon-alpha2a and ribavirin versus pegylated interferon-alpha2b and ribavirin in chronic hepatitis C: a meta-analysis. Drugs 2013; 73: 263-277.
106. Rizzari C, et al. Optimizing asparaginase therapy for acute lymphoblastic leukemia. Curr Opin Oncol 2013; 25 (Suppl 1): S1-S9.
107. Schmidt SR. Fusion-proteins as biopharmaceuticals--applications and challenges. Curr Opin Drug Discov Devel 2009; 12: 284-295.
108. European Medicines Agency. PRAC recommends suspending marketing authorisations for infusion solutions containing hydroxyethyl startch. 14 June 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Solutions_for_infusion_containing_hydroxyethyl_starch/Recommendation_provided_by_Pharmacovigilance:Risk_Assessment_Committee?WC500144448.pdf. Last accessed January 2014.
109. Metzner HJ, et al. Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin. Thromb Haemost 2013; 110: 931-939.
110. van der Flier A, et al. Different Contribution of Hematopoietic and Somatic Cell Types Expressing FcRn to the Prolonged Half-Life of Recombinant Factor VIII Fc and Recombinant FIX Fc. ASH Annual Meeting Abstracts 2012; 120: 1103.
111. Ivens IA, et al. PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers. Haemophilia 2013; 19: 11-20.
112. Bjoernsdottir I, et al. Excretion and pharmacokinetics of glycopegylated rFVIII (N8-GP) after single intravenous dose administration to rats. J Thromb Haemost 2013; 11 (Suppl 2): 579 (Abstract PB 1.55-2).
113. Kang JS, et al. Emerging PEGylated drugs. Expert Opin Emerg Drugs 2009; 14: 363-380.
114. Armstrong JK, et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007; 110: 103-111.
115. Garay RP, et al. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv 2012; 9: 1319-1323.
116. Reipert B, et al. Does PEGylated factor VIII induce antibodies against PEG? Haemophilia 2012; 18 (Suppl 3): 28-29 (Abstract FP-MO-03.2-5).
117. Bendele A, et al. Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol Sci 1998; 42: 152-157.
118. Rudmann DG, et al. High molecular weight polyethylene glycol cellular distribution and PEG-associated cytoplasmic vacuolation is molecular weight dependent and does not require conjugation to proteins. Toxicol Pathol 2013; 41: 970-983.
119. EMA assessment report for Cimzia. Available at: http://www.ema.europa.eu?docs/en_GB/document_library/EPAR_-_Public_assessment_report?human/001037/WC500069735.pdf. Accessed June 2014.